From: Targeting FBPase is an emerging novel approach for cancer therapy
Type of cancer | FBPase expression | Change in expression over disease progression | Prognostic significance | Reference(s) |
---|---|---|---|---|
Breast cancer | Lower in animal model, human breast cancer [74,75,76], basal-like breast cancer cell lines [20], triple-negative breast cancer but not in luminal cell lines [19] and brain metastatic cells [21]. Data mining shown FBP1 over-expression were common in breast cancer irrespective of histological type in cell lines and human breast cancer [20] | Expression inhibited tumorigenicity in vitro and tumor-formation in vivo [20, 22] but promoted the growth of brain metastasis [21]. FBP1 expression associated with nuclear grade and tumor stage [18] | Loss of FBP1 expression associated with poor survival [18, 20, 22]. But data mining shown no correlation between FBP1 and prognosis in triple-negative breast cancer [20] | |
Colon cancer | Lower in cancer cell lines and in human colon cancer [17] | Overexpression reduced cancer cell colony formation and inhibited the growth of cancer cells [17] | Â | [17] |
Gastric cancer | Downregulated in gastric cancer cell lines and gastric carcinomas [17, 25, 26] | Overexpression inhibited proliferation inhibition in vitro as well as xenograft tumor growth in vivo [25, 26] | Absent or low FBP2 expression correlated with poor survival [25] | |
Liver cancer | Decreased in 3-methyl-4-dimethyl aminoazobenzene (3MeDAB) induced [77] and choline-deficient diet-induced hepatocellular carcinoma model [78]; Decreased in most human liver cancer cell lines [14, 17] and in human hepatocellular carcinoma [15,16,17, 77, 79,80,81,82] | Low expression correlated with highly malignant phenotype, including large tumor size, poor differentiation, advanced tumor stage [15, 80,81,82], vascular cell invasion and high pathological grade [14] | Loss of FBP1 expression associated with poor overall survival and higher tumor recurrence rates [14, 15, 79, 81, 82] | |
Lung cancer | Loss in lung cancer cells [12, 13] and in human lung cancer tissues [13, 83, 84] | Forced expression inhibited tumorigenesis and invasion in lung cancer cells [12, 13] and cancer progression in human lung cancer [13] | Low FBP1 expression correlated with poor overall survival [13] | |
Pancreatic cancer | Â | FBP1 expression inversely correlated with tumor grades and prognosis [27, 28] | ||
Renal carcinoma | Ubiquitous loss in clear cell renal cell carcinoma [23, 24, 85, 86] | FBP1 expression in several renal cancer cell lines inhibited their growth. Suppression of FBP1 correlated with advanced tumour stage [24]. But no correlation was found between clinicopathological factors, including age, gender, T stage, Fuhrman grade and expression of FBP1 expression in another study [23] | Suppression correlated with worse patient prognosis [24] | |
Small intestinal neuroendocrine tumour | Comprehensive integrated genomic analysis shown epigenetically dysregulation [87] | Â | Â | [87] |